Sangamo (SGMO) Posts Wider than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Join SI Premium – FREE
Sangamo Biosciences Inc. (Nasdaq: SGMO) reported Q1 loss of $0.21, $0.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $4.09 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sangamo picks Lilly and PTC as buyers in bankruptcy auction
- Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
- Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
